Biolargo (BLGO) director Bray awarded 115,741-share stock option for board fees

Rhea-AI Filing Summary

BIOLARGO, INC. director Christina Elaine Bray received an option grant as compensation for board service. She was awarded an option to purchase 115,741 shares of Common Stock at an exercise price of $0.162 per share, issued under the company’s 2024 Equity Incentive Plan.

The option was granted in lieu of $18,750 of cash fees for the most recently completed quarter. After this award, she beneficially holds derivative securities representing 1,381,502 underlying shares directly, reflecting routine, equity-based director compensation rather than an open-market transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bray Christina Elaine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	115,741	$0.00	--

Holdings After Transaction: Option to Purchase Common Stock — 1,381,502 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 115,741 shares Exercise price: $0.162 per share Cash fees replaced: $18,750 +3 more

6 metrics

Option grant size 115,741 shares Option to Purchase Common Stock granted March 31, 2026

Exercise price $0.162 per share Exercise price of the director stock option

Cash fees replaced $18,750 Quarterly board fees paid via option grant

Post-grant derivative holdings 1,381,502 shares Total underlying shares following this derivative award

Grant date March 31, 2026 Option grant and exercise date

Expiration date March 31, 2036 Option expiration under the grant terms

Key Terms

Option to Purchase Common Stock, exercise price, Equity Incentive Plan, Grant, award, or other acquisition

4 terms

Option to Purchase Common Stock financial

"security_title: "Option to Purchase Common Stock""

exercise price financial

"equal to the amount of fees due divided by the exercise price of the Option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bray Christina Elaine

(Last) (First) (Middle)

14921 CHESTNUT ST.

(Street)

WESTMINSTER CALIFORNIA 92683

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.162	03/31/2026		A		115,741		03/31/2026	03/31/2036	Common Stock	115,741	(1)	1,381,502	D

Explanation of Responses:

1. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan. The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.

	/s/ John R. Browning, attorney-in-fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did BIOLARGO (BLGO) director Christina Elaine Bray report on this Form 4?

Christina Elaine Bray reported receiving an option to purchase 115,741 shares of BIOLARGO common stock. The option is part of her director compensation and was granted instead of cash fees for the most recently completed quarterly board service period.

What are the key terms of Christina Elaine Bray’s BIOLARGO stock option grant?

The option covers 115,741 BIOLARGO common shares at an exercise price of $0.162 per share. It was granted on March 31, 2026 and is scheduled to expire on March 31, 2036, providing a long-term equity incentive for the director.

How was the BIOLARGO (BLGO) director option grant related to board fees?

The option was issued as payment for $18,750 in fees owed to Christina Elaine Bray for her most recently completed quarterly board service. The number of option shares equals those fees divided by the $0.162 per share exercise price specified in the grant.

Is Christina Elaine Bray’s BIOLARGO Form 4 transaction a market purchase or sale?

The Form 4 shows a compensation-related award, not a market trade. She acquired an option grant coded as “A” for grant or award, with no cash paid and no open-market buying or selling of BIOLARGO common stock involved in this transaction.

How many BIOLARGO shares does Christina Elaine Bray hold after this option award?

After this award, she holds derivative securities for a total of 1,381,502 underlying BIOLARGO common shares directly. This figure reflects her aggregate derivative position reported in the filing following the 115,741-share option grant recorded on March 31, 2026.